These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 8610959)
1. Tamoxifen-induced steatohepatitis. Van Hoof M; Rahier J; Horsmans Y Ann Intern Med; 1996 May; 124(9):855-6. PubMed ID: 8610959 [No Abstract] [Full Text] [Related]
2. [Cirrhosis with non alcoholic steatohepatitis: role of tamoxifen]. Dray X; Tainturier MH; De La Lande P; Marty O; Mallet L Gastroenterol Clin Biol; 2000 Nov; 24(11):1122-3. PubMed ID: 11139682 [TBL] [Abstract][Full Text] [Related]
6. Tamoxifen-induced transient multifocal hepatic fatty infiltration. Cai Q; Bensen M; Greene R; Kirchner J Am J Gastroenterol; 2000 Jan; 95(1):277-9. PubMed ID: 10638597 [TBL] [Abstract][Full Text] [Related]
7. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Murata Y; Ogawa Y; Saibara T; Nishioka A; Fujiwara Y; Fukumoto M; Inomata T; Enzan H; Onishi S; Yoshida S Oncol Rep; 2000; 7(6):1299-304. PubMed ID: 11032933 [TBL] [Abstract][Full Text] [Related]
8. Tamoxifen-induced non-alcoholic steatohepatitis in patients with breast cancer: determination of a suitable biopsy site for diagnosis. Murata Y; Ogawa Y; Saibara T; Nishioka A; Takeuchi N; Kariya S; Onishi S; Yoshida S Oncol Rep; 2003; 10(1):97-100. PubMed ID: 12469151 [TBL] [Abstract][Full Text] [Related]
9. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796 [TBL] [Abstract][Full Text] [Related]
10. Fatty liver and drugs. Grieco A; Forgione A; Miele L; Vero V; Greco AV; Gasbarrini A; Gasbarrini G Eur Rev Med Pharmacol Sci; 2005; 9(5):261-3. PubMed ID: 16237810 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-associated steatohepatitis--report of three cases. Pinto HC; Baptista A; Camilo ME; de Costa EB; Valente A; de Moura MC J Hepatol; 1995 Jul; 23(1):95-7. PubMed ID: 8530816 [TBL] [Abstract][Full Text] [Related]
15. Steatohepatitis: a tale of two "hits"? Day CP; James OF Gastroenterology; 1998 Apr; 114(4):842-5. PubMed ID: 9547102 [No Abstract] [Full Text] [Related]
16. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Rabinowich L; Shibolet O Biomed Res Int; 2015; 2015():168905. PubMed ID: 26273591 [TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going? Osman KA; Osman MM; Ahmed MH Expert Opin Drug Saf; 2007 Jan; 6(1):1-4. PubMed ID: 17181445 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-associated steatohepatitis. Meunier L; Larrey D Ann Hepatol; 2020; 19(6):597-601. PubMed ID: 32061473 [TBL] [Abstract][Full Text] [Related]
19. Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Saibara T; Onishi S; Ogawa Y; Yoshida S; Enzan H Lancet; 1999 May; 353(9166):1802. PubMed ID: 10348023 [No Abstract] [Full Text] [Related]
20. Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist. Ahmed MH; Osman KA Breast Cancer Res Treat; 2006 May; 97(2):223-4. PubMed ID: 16322887 [No Abstract] [Full Text] [Related] [Next] [New Search]